19 July 2022 | News
The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment in China, evaluated through a randomized, double-blind, placebo-controlled trial
Image credit: shutterstock
Brii Biosciences has announced that TSB Therapeutics (Beijing), a joint venture majority-owned by the company, is partnering with China Resources Pharmaceutical Commercial Group (CR Pharma Comm) to advance stockpiling, channel distribution and hospital access for the company's long-acting neutralizing monoclonal antibody (mAb) therapy, the amubarvimab/romlusevimab combination.
The two parties are working together to ensure timely drug supply that supports the COVID-19 pandemic prevention and control efforts in China. The collaboration will also explore other novel partnership opportunities to enable expanded access of the combination therapy in China.
Through the joint efforts of Brii Bio and CR Pharma Comm, the first batch of the combination therapy was successfully delivered to the Third People's Hospital of Shenzhen, and the first patient was dosed. From May to December 2021, Brii Bio donated nearly 3,000 doses of the amubarvimab/romlusevimab combination for emergency use in 22 hospitals in 21 cities as part of its commitment to ensure humanitarian access and to help curb the outbreaks of the pandemic. Nearly 1,000 patients received the treatment of the combination therapy. These real-world data provide important clinical application and safety data in China. The subsidiaries of CR Pharma Comm made a great contribution in delivering the drugs to the hospitals for clinical treatment of patients.
With the commercialization of the amubarvimab/romlusevimab combination, the company will actively cooperate with its business partners, make every effort to improve accessibility, and advance drug stockpiling at all levels, to quickly respond to the sudden outbreak of COVID-19 and protect peoples' lives.